Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Silence Therapeutics (SLN) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for Silence Therapeutics (SLN) over the last 3 years, with Sep 2025 value amounting to -0.60%.

  • Silence Therapeutics' Return on Capital Employed fell 11.00% to -0.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.60%, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -0.44% for FY2024, which is 82.00% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Return on Capital Employed is -0.60%, which was down 10.76% from -0.54% recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Return on Capital Employed ranged from a high of 346.24% in Q3 2021 and a low of -2.15% during Q1 2022.
  • Its 3-year average for Return on Capital Employed is -0.78%, with a median of -0.54% in 2025.
  • Per our database at Business Quant, Silence Therapeutics' Return on Capital Employed surged by 104bps in 2024 and then fell by 18bps in 2025.
  • Silence Therapeutics' Return on Capital Employed (Quarterly) stood at 346.24% in 2021, then reached -2.15% in 2022, then skyrocketed by 77bps to -1.23% in 2023, then soared by 80bps to -0.43% in 2024, then dropped by 11bps to -0.60% in 2025.
  • Its Return on Capital Employed was -0.60% in Q3 2025, compared to -0.54% in Q2 2025 and -0.49% in Q1 2025.